GRAL Share Price Performance
US$51.74
27.77 (115.81%)
28.5% undervalued intrinsic discount
US$72.40
Fair Value
Price US$51.74
AnalystConsensusTarget US$72.40
AnalystHighTarget US$130.00
AnalystLowTarget US$60.00
Fair ValueUS$72.40
Share Pricen/a
GRAIL, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 28 Fair Values set on narratives written by author
GRAL Community Narratives
AN
Fair Value US$72.4 28.5% undervalued intrinsic discount
GRAL: Execution Risks Remain High Amid PATHFINDER 2 Progress And Regulatory Shifts
0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AN
Fair Value US$130 60.2% undervalued intrinsic discount
NHS Trial Momentum And Medicare Pathway Will Support Long Term Multi Cancer Screening Adoption
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$60 13.8% undervalued intrinsic discount
Clinical Trial Setbacks And Reimbursement Delays Will Eventually Support Early Cancer Detection Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
GRAL: Execution Risks Remain High Amid PATHFINDER 2 Progress And Regulatory Shifts
Key Takeaways Positive clinical results and expanding commercial adoption of Galleri position GRAIL for strong regulatory momentum, payer support, and accelerated, diversified revenue growth. Enhanced process scalability and disciplined cost control are improving margins and reducing losses, while global partnerships and demographic trends drive long-term opportunity.Read more
780
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AN
US$72.4
28.5% undervalued intrinsic discount
Fair Value
Profit Margin
14.76%
Future PE
110.63x
Price in 2029
US$88.52
Clinical Trial Setbacks And Reimbursement Delays Will Eventually Support Early Cancer Detection Potential
Catalysts About GRAIL GRAIL focuses on multi cancer early detection through its Galleri screening test and related clinical programs. What are the underlying business or industry changes driving this perspective?Read more
10
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$60
13.8% undervalued intrinsic discount
Fair Value
Profit Margin
10.89%
Future PE
154.7x
Price in 2029
US$73.74
NHS Trial Momentum And Medicare Pathway Will Support Long Term Multi Cancer Screening Adoption
Catalysts About GRAIL GRAIL develops and commercializes Galleri, a blood based multi cancer early detection test aimed at finding cancers at earlier stages. What are the underlying business or industry changes driving this perspective?Read more
29
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$130
60.2% undervalued intrinsic discount
Fair Value
Profit Margin
15.7%
Future PE
146.51x
Price in 2029
US$159.68
Trending Discussion
Recently Updated Narratives
AN
GRAL: Future Returns Will Hinge On Upcoming Regulatory And Coverage Milestones
Fair Value: US$72.4 28.5% undervalued intrinsic discount
18 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Clinical Trial Setbacks And Reimbursement Delays Will Eventually Support Early Cancer Detection Potential
Fair Value: US$60 13.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
NHS Trial Momentum And Medicare Pathway Will Support Long Term Multi Cancer Screening Adoption
Fair Value: US$130 60.2% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
GRAIL, Inc. Key Details
About GRAL
- Founded
- 2015
- Employees
- 910
- CEO
- WebsiteView website
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
